Abstract：【Objective】 To study the application values of mean platelet volume (MPV) and embolism risk assessment in elderly patients with atrial fibrillation . 【Methods】Simple atrial fibrillation (39 cases, negative group) and atrial fibrillation combined with vascular lesions or embolization (48 cases, positive group) were collected. General clinical data of patients and routine blood MPV values of the two groups were compared and analyzed. 【Results】The CHA2DS2-VASc method was used for the evaluation, i.e. congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65~74, and sex (female). The CHA2DS2-VASc score(2.38±1.18) of the negative group was lower than that of the positive group (3.77±1.28), and the difference was statistically significant (P<0.05). Even after 3 points (1 for vascular disease and 2 for stroke/TIA) were subtracted from the score of the positive group, its CHA2DS2-VASc score (2.98±1.25)was still higher than that of the negative group (P<0.05). The MPV value in the negative group (10.39±1.07)fL was lower than that in the positive group (11.58±1.24)fL. The difference in the two groups was statistically significant (P<0.05). The area under the ROC curve was 0.773, which predicted high-risk embolism in elderly patients with atrial fibrillation. According to the ROC curve, the cutoff value of MPV was set at 11.1/11.2 fL. Then, the maximum index approached 0.446 with its sensitivity and specificity rate being 64.6% and 82.1%, respectively. 【Conclusion】 MPV is one of the effective indicators to assess the risk of embolism in elderly patients with atrial fibrillation. It has high sensitivity and specificity, and it is worthy application in the clinic.
王慕秋;高敏. 血小板平均容积在老年房颤患者栓塞中的风险评估价值[J]. 医学临床研究, 2016, 33(12): 2309-2313.
WANG Mu-qiu, GAO Min. Association between Mean Platelet Volume and Embolism in Elderly Patients with Atrial Fibrillation. JOURNAL OF CLINICAL RESEARCH, 2016, 33(12): 2309-2313.
[1] Schnabel RB, Yin X, Gona P,et al.50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study [J].Lancet,2015,386(9989):154-162. [2] Tomlin AM.Atrial fibrillation in New Zealand primary care: Prevalence, risk factors for stroke and the management of thromboembolic risk [J].Eur J Prev Cardiol,2016. [3] Gasparyan AY, Ayvazyan L, Mikhailidis DP, et al. Mean platelet volume: a link between thrombosis and inflammation [J].Curr Pharm Des,2011,17(1):47-58. [4] Watson T.Relationship of indices of inflammation and thrombogenesis to arrhythmia burden in paroxysmal atrial fibrillation.[J].Chest,2010,137(4):869-876. [5] Kirchhof P, Benussi S, Kotecha D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J].Europace,2016,18(11):1609-1678. [6] Melgaard L, Gorst-Rasmussen A, Lane DA, et al. Assessment of the CHA2DS2-vasc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation [J].JAMA,2015,314(10):1030-1038. [7] Hankey GJ. The ABC-stroke risk score was superior to the CHA2DS2-VASc score for predicting stroke in atrial fibrillation[J].Ann Intern Med,2016,164(12):C69. [8] Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc >/=1, or higher[J]?Thromb Haemost,2015,113(6):1165-1169.
2016, Vol. 33 
